
Across 26 years at Lilly and seven as Neurocrine's chief medical officer, Eiry Roberts learned that drug development is less a straight line than a chain of judgment calls. Her next chapter puts that operating memory to work in the boardroom.

Reinilde Heyrman has spent decades turning clinical uncertainty into decisions. Her method is neither grand nor theatrical: start with the science, plan for the detour, and make sure someone owns the next move.